161 related articles for article (PubMed ID: 35816283)
1. 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence.
Jung YS; Kim S; Kim HY; Noh SJ; Park JH; Park CH
J Gastroenterol Hepatol; 2022 Oct; 37(10):1911-1918. PubMed ID: 35816283
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of
Jung YS; Kim S; Kim HY; Noh SJ; Park JH; Sohn CI; Park CH
Gut Liver; 2023 Sep; 17(5):711-721. PubMed ID: 36510776
[TBL] [Abstract][Full Text] [Related]
3. Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of
Choi YJ; Lee YC; Kim JM; Kim JI; Moon JS; Lim YJ; Baik GH; Son BK; Lee HL; Kim KO; Kim N; Ko KH; Jung HK; Shim KN; Chun HJ; Kim BW; Lee H; Kim JH; Chung H; Kim SG; Jang JY
Gut Liver; 2022 Jul; 16(4):535-546. PubMed ID: 35791797
[TBL] [Abstract][Full Text] [Related]
4. Treatment of
Kanu JE; Soldera J
World J Gastroenterol; 2024 Mar; 30(9):1213-1223. PubMed ID: 38577188
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for
Park CH; Song MJ; Jung BW; Park JH; Jung YS
J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36422094
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line
Kim JY; Lee SY; Kim H; Kim JH; Sung IK; Park HS
Yonsei Med J; 2021 Aug; 62(8):708-716. PubMed ID: 34296548
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials.
Zhang M; Pang M; Zhang M
Clinics (Sao Paulo); 2022; 77():100058. PubMed ID: 35810638
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study.
Kim JS; Ko W; Chung JW; Kim TH
Helicobacter; 2023 Jun; 28(3):e12977. PubMed ID: 37083222
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy of Tegoprazan vs Esomeprazole/Sodium Bicarbonate for the Treatment of Helicobacter pylori Infection.
Park CH; Park JH; Jung YS
Clin Transl Gastroenterol; 2023 Nov; 14(11):e00632. PubMed ID: 37561041
[TBL] [Abstract][Full Text] [Related]
10. Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication.
Kwon YH; Jeon SW; Nam SY; Lee DW; Park JH; Bae HJ
Korean J Intern Med; 2023 Jul; 38(4):493-503. PubMed ID: 37369525
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Suzuki S; Gotoda T; Kusano C; Iwatsuka K; Moriyama M
Am J Gastroenterol; 2016 Jul; 111(7):949-56. PubMed ID: 27185079
[TBL] [Abstract][Full Text] [Related]
12. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
[TBL] [Abstract][Full Text] [Related]
13. Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for
Kim BJ; Lee H; Lee YC; Jeon SW; Kim GH; Kim HS; Sung JK; Lee DH; Kim HU; Park MI; Choi IJ; Yoon SM; Kim SW; Baik GH; Lee JY; Kim JI; Kim SG; Kim J; Lee J; Kim JG; Kim JJ;
Gut Liver; 2019 Sep; 13(5):531-540. PubMed ID: 31505907
[TBL] [Abstract][Full Text] [Related]
14. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.
Kim YS; Kim SJ; Yoon JH; Suk KT; Kim JB; Kim DJ; Kim DY; Min HJ; Park SH; Shin WG; Kim KH; Kim HY; Baik GH
Aliment Pharmacol Ther; 2011 Nov; 34(9):1098-105. PubMed ID: 21923713
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant
Lee JW; Kim N; Nam RH; Yu JE; Son JH; Lee SM; Lee DH
Gut Liver; 2021 Jan; 15(1):53-60. PubMed ID: 33191308
[TBL] [Abstract][Full Text] [Related]
17. Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies.
Sezgin O; Aydın MK; Özdemir AA; Kanık AE
Turk J Gastroenterol; 2019 May; 30(5):420-435. PubMed ID: 31060997
[TBL] [Abstract][Full Text] [Related]
18. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.
Matsumoto H; Shiotani A; Katsumata R; Fujita M; Nakato R; Murao T; Ishii M; Kamada T; Haruma K; Graham DY
Dig Dis Sci; 2016 Nov; 61(11):3215-3220. PubMed ID: 27659671
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia.
Chan CC; Chien NH; Lee CL; Yang YC; Hung CS; Tu TC; Wu CH
BMC Gastroenterol; 2015 Dec; 15():170. PubMed ID: 26635102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
